Trikafta Rescues CFTR and Lowers Monocyte P2X7R-induced Inflammasome Activation in Cystic Fibrosis
- 1 April 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 205 (7) , 783-794
Abstract
Rationale: Cystic fibrosis (CF) is caused by mutations in the CFTR (CF transmembrane conductance regulator) gene and is characterized by sustained inflammation. ATP triggers IL-1β secretion via P2X7R (P2X7 receptor) and activation of the NLRP3 (NOD-, LRR-, and pyrin domain–containing protein 3) inflammasome. Objectives: To explore the effect of the CFTR modulator elexacaftor/tezacaftor/ivacaftor (Trikafta) on CFTR expression and the ATP/P2X7R signaling axis in monocytes and on circulating proinflammatory markers. Methods: Inflammatory mediators were detected in blood from 42 patients with CF before and after 3 months of Trikafta therapy. Markers of inflammasome activation and IL-1β secretion were measured in monocytes before and after stimulation with ATP and LPS, in the presence or absence of the P2X7R inhibitor A438079. Measurements and Main Results: P2X7R is overexpressed in CF monocytes, and receptor inhibition decreased NLRP3 expression, caspase-1 activation, and IL-1β secretion. In vitro and in vivo, P2X7R expression is regulated by CFTR function and intracellular chloride (Cl−) levels. Trikafta therapy restored CFTR expression yet decreased P2X7R in CF monocytes, resulting in normalized Cl− and potassium efflux, and reduced intracellular calcium levels. CFTR modulator therapy decreased circulating levels of ATP and LPS and reduced inflammasome activation and IL-1β secretion. Conclusions: P2X7R expression is regulated by intracellular Cl− levels and in CF monocytes promotes inflammasome activation. Trikafta therapy significantly increased CFTR protein expression and reduced ATP/P2X7R–induced inflammasome activation. P2X7R may therefore be a promising target for reducing inflammation in patients with CF who are noneligible for Trikafta or other CFTR modulator therapy.Keywords
Funding Information
- Cystic Fibrosis Foundation (REEVES21G0)
- Cystic Fibrosis Foundation (REEVES21G0)
This publication has 50 references indexed in Scilit:
- Purinergic Receptor Inhibition Prevents the Development of Smoke-Induced Lung Injury and EmphysemaThe Journal of Immunology, 2010
- Purinergic Signaling: A Fundamental Mechanism in Neutrophil ActivationScience Signaling, 2010
- Intracellular chloride regulates cell proliferation through the activation of stress‐activated protein kinases in MKN28 human gastric cancer cellsJournal of Cellular Physiology, 2010
- Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophagesBlood, 2009
- Evidence for direct CFTR inhibition by CFTRinh-172 based on Arg347 mutagenesisBiochemical Journal, 2008
- Pulmonary TH2 response in Pseudomonas aeruginosa–infected patients with cystic fibrosisJournal of Allergy and Clinical Immunology, 2006
- Measurement of free and bound fractions of extracellular ATP in biological solutions using bioluminescenceLuminescence, 2005
- Mechanisms of caspase-1 activation by P2X7 receptor-mediated K+ releaseAmerican Journal of Physiology-Cell Physiology, 2004
- Chloride, a New Environmental Signal Molecule Involved in Gene Regulation in a Moderately Halophilic Bacterium,Halobacillus halophilusJournal of Bacteriology, 2002
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989